ReviewClinical science (London, England : 1979)2025
COPD: the role of neutrophils in inflammation, pathophysiology, and as drug targets.
Review in Clinical science (London, England : 1979), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biologic therapies targeting type 2 inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomised controlled trials.BMJ open respiratory research · 2026Pooled it
- Different Inflammatory Phenotypes and Immune Endotypes Drive Disease Heterogeneity in Asthma and COPD.Clinical reviews in allergy & immunology · 2026Review
- COPD Biologics: Right Patient, Right Pathway, Right Time.Pulmonary therapy · 2026Review
- The cell with many faces: lung macrophage plasticity and function in response to environmental and pathogenic insults.Physiological reviews · 2026Review
- Immune research progress of Slit2-Robo signaling axis in chronic obstructive pulmonary disease: a narrative review.Journal of thoracic disease · 2026Review
- Loneliness in Chronic Obstructive Pulmonary Disease: A Multidimensional Determinant of Clinical Outcomes and Disease Management.Journal of clinical medicine · 2026Review
- Cryptochrome Loss Drives COPD-like Lung Pathology through Disrupted Alveolar Epithelial Proliferation and Immune Homeostasis.bioRxiv : the preprint server for biology · 2026Article
- Clinical and phenotypic characteristics of chronic cough patients without sputum eosinophilia.BMC pulmonary medicine · 2026Article
- Neutrophil migration in the lung is altered by alveolar collapse and stretch.bioRxiv : the preprint server for biology · 2026Article
- The Evolving Landscape of COPD Typization.Medicina (Kaunas, Lithuania) · 2026Review
- RANKL promotes airway inflammation via pro-inflammatory alveolar macrophage activation in COPD.Respiratory research · 2026Article
- From clinical phenotypes to cellular mechanisms: a precision medicine framework for COPD.Frontiers in immunology · 2026Review
- Epitranscriptomics, immunometabolism, and NETosis: unlocking novel mechanisms of traditional Chinese medicine in COPD.Frontiers in immunology · 2026Review
- Mitochondrial reprogramming of neutrophil extracellular traps in chronic obstructive pulmonary disease and asthma: toward a phenotype-driven therapeutic framework.Frontiers in immunology · 2026Review
- Impact of Neutrophils on the Tissue Microenvironment During Intestinal Inflammation.Journal of inflammation research · 2026Review
- Neutrophil Plasticity in Airway Disease: Balancing Damage and Repair.Journal of innate immunity · 2026Review
- Mechanisms by which complex carbohydrates influence immune imbalance in COPD via the gut-lung axis: from colonic fermentation to pulmonary immune responses.Frontiers in nutrition · 2026Review
- Beyond pathogens: a narrative review of the immunological nexus of damage-associated molecular patterns and inflammasome activation in sterile AECOPD.Frontiers in immunology · 2026Review
- Sex-dependent transcriptional and epigenetic regulation of neutrophil inflammatory programs in COPD.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutrophils are innate immune effector cells that play a vital role in host defense against infection. They exert antimicrobial activities through degranulation, phagocytosis, intracellular killing, production of reactive oxygen species, and neutrophil extracellular traps. Dysregulation of neutrophil abundance, phenotype, and immune activity is a commonly observed inflammatory feature of chronic obstructive pulmonary disease (COPD), a chronic inflammatory disorder of the lungs with no effective cure. Here, we review the clinical association and involvement of neutrophils in COPD pathogenesis, progression, and exacerbation. The association between neutrophilia, airway microbial imbalance (dysbiosis), and clinical manifestations of COPD is described. We summarize the impact (or lack of) of current treatments, including inhaled corticosteroids, macrolide antibiotics, and phosphodiesterase inhibitors, on neutrophilic inflammation or neutrophilia-associated features. Finally, we review potential future therapeutic options to address neutrophilic inflammation in COPD currently in clinical development, including anti-alarmins and inhibitors of neutrophil mediators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.